EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

GLP ‐ 1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score Matching

Jonggi Choi, Tushar Kamath, Vy H Nguyen, Eric Przybyszewski, Jiunn Song, Allison Carroll, Megan Michta, Erik Almazan, Tracey G Simon, Raymond T Chung

Liver International · 2025-12 · 45 (12)

DOI: 10.1111/liv.70447 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 18.11.2025. Verfasst von Jonggi Choi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Liver Cirrhosis, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims GLP‐1 receptor agonists (GLP‐1RA) are widely used in type 2 diabetes mellitus (T2DM) and may confer hepatoprotective effects in metabolic dysfunction‐associated steatotic liver disease (MASLD). Their impact on liver fibrosis progression in real‐world clinical settings remains unclear. This study evaluated the link between GLP‐1RA use and liver fibrosis progression in T2DM patients with early‐stage MASLD.

Methods

We conducted a retrospective cohort study emulating a target trial using electronic health records from the Mass General Brigham (MGB) system between 2010 and 2023. Adults with MASLD and T2DM who initiated GLP‐1RA or dipeptidyl peptidase‐4 inhibitor (DPP‐4i) therapy and had baseline Fibrosis‐4 (FIB‐4) scores < 2.67 were included. Propensity score matching (1:1) was applied to balance baseline covariates between groups. The primary outcome was progression to high‐risk FIB‐4 (> 2.67), confirmed by two consecutive values ≥ 90 days apart within a one‐year period. The secondary outcome was a composite of cirrhosis, hepatic decompensation, hepatocellular carcinoma, or liver transplantation.

Results

A total of 2238 matched pairs were analysed. GLP‐1RA use was associated with a lower risk of fibrosis progression compared to DPP‐4i (incidence rate 3.25 vs. 4.29 per 100 person‐years; HR 0.75, 95% CI 0.65–0.87). Results were consistent in per‐protocol (HR 0.80) and landmark sensitivity analyses. The risk reduction was also observed across subgroups, including those with low baseline FIB‐4, BMI < 30, and users of statins, aspirin or metformin. No significant difference was found in secondary liver‐related outcomes (HR 0.98, 95% CI 0.72–1.34).

Conclusion

GLP‐1RA use significantly reduced the risk of liver fibrosis progression in patients with MASLD and T2DM, supporting its potential role in early disease modification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Liver CirrhosisGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsFatty LiverHumansMaleFemaleMiddle AgedRetrospective StudiesDisease ProgressionPropensity ScoreDipeptidyl-Peptidase IV InhibitorsAged

Stichwörter der Autor:innen

GLP‐1RAMASLDliver fibrosis

Substanzen

Dipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Liver Center, Gastroenterology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Choi, J., Kamath, T., Nguyen, V. H., Przybyszewski, E., Song, J., Carroll, A., Michta, M., Almazan, E., Simon, T. G., & Chung, R. T. (2025). GLP ‐ 1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score Matching. Liver International, 45(12). https://doi.org/10.1111/liv.70447

Vancouver

Choi J, Kamath T, Nguyen VH, Przybyszewski E, Song J, Carroll A, et al. GLP ‐ 1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score Matching. Liver International. 2025;45(12). doi:10.1111/liv.70447

BibTeX
@article{Choi2025,
  author = {Choi, Jonggi and Kamath, Tushar and Nguyen, Vy H and Przybyszewski, Eric and Song, Jiunn and Carroll, Allison and Michta, Megan and Almazan, Erik and Simon, Tracey G and Chung, Raymond T},
  title = {GLP ‐ 1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score Matching},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {12},
  doi = {10.1111/liv.70447}
}
Kostenlos starten →